We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kanabo Group Plc | LSE:KNB | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.70 | 1.50 | 1.90 | 1.70 | 1.70 | 1.70 | 184,259 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 603k | -6.87M | -0.0109 | -1.56 | 10.75M |
From Apr 2022 to Apr 2024
TIDMKNB
RNS Number : 1801O
Kanabo Group PLC
08 June 2022
Kanabo Group Plc.
(" Kanabo " or the "Company")
Notice of AGM
Kanabo Group Plc. (LON: KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, announces that its Annual General Meeting ("AGM") will be held at Asserson Law Offices of Central Court, 25 Southampton Buildings, Holborn, London, WC2A 1AL on Thursday 30 June 2022 at 11:00 am.
A notice of AGM, together with a form of proxy and a copy of the annual report has been sent to the shareholders of the Company (" Shareholders "). The notice of AGM will also shortly be available for inspection on the Kanabo website .
For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:
Kanabo Group Plc Via Vox Markets Avihu Tamir, CEO Peterhouse Capital Ltd (Financial Tel: +44 (0)20 7469 0930 Adviser) Eran Zucker / Lauren Riley Vox Markets (Investor Relations) KanaboGroup@voxmarkets.co.uk Kat Perez kperez@voxmarkets.co.uk
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.
It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAEAFKPEDKAEFA
(END) Dow Jones Newswires
June 08, 2022 08:00 ET (12:00 GMT)
1 Year Kanabo Chart |
1 Month Kanabo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
